BRILINTA (ticagrelor) is a prescription medication developed by AstraZeneca, primarily used for the prevention of thrombotic cardiovascular events in patients with a history of acute coronary syndrome. One of the common dosages prescribed is 90 mg, which plays a key role in treating patients at risk of serious heart-related conditions.
For more detailed information on how BRILINTA 90 MG works and its potential side effects, you can refer to this link.
How BRILINTA 90 MG Works
BRILINTA functions as an antiplatelet agent, inhibiting platelet activation and aggregation, which prevents the formation of blood clots. Here are some key mechanisms:
- Inhibition of ADP receptors: Ticagrelor blocks P2Y12 receptors on platelets, preventing ADP from activating them.
- Rapid onset and offset: Compared to clopidogrel, BRILINTA acts quickly, offering prompt anticoagulant effects.
- Reversible binding: Unlike some antiplatelet medications, BRILINTA binds reversibly to its target, which allows for a more controlled reversal of its effects if necessary.
Indications for Use
BRILINTA 90 MG is indicated for various patients, including:
- Those recovering from a heart attack.
- Patients with unstable angina.
- Individuals undergoing certain cardiovascular interventions, like stenting.
Potential Side Effects
Like any medication, BRILINTA may cause side effects. Commonly experienced adverse reactions include:
- Bleeding: Increased risk of bleeding due to its blood-thinning properties.
- Shortness of breath: Some patients report breathing difficulties, which may be dose-dependent.
- Gastrointestinal issues: Nausea, vomiting, and stomach pain may occur.
Conclusion
BRILINTA 90 MG by AstraZeneca is a crucial element in the management of patients at risk for serious cardiovascular events. While effective, it is important for patients to discuss potential side effects and contraindications with their healthcare providers to ensure safe usage. Always follow a physician’s guidance for treatment and management of heart health.